Controlled trials are ubiquitously used to investigate the effect of a medical treatment. The trial outcome can be dependent on a set of patient covariates. Traditional approaches have relied primarily on randomized patient sampling and allocation to treatment and control groups. However, when covariate data for a large set of patients are available and the dependence of the outcome on the covariates is of interest, one can potentially design treatment/control groups that provide better estimates of the covariatedependent effects of the treatment or provide similarly accurate estimates with a smaller trial cohort size. In this article, we develop an approach that uses optimal Design Of Experiments (DOE) concepts to select the patients for the treatment and control groups upfront, based on their covariate values, in a manner that optimizes the information content in the data. For the optimal treatment and control groups selection, we develop simple guidelines and an optimization algorithm that achieves much more accurate estimates of the covariate-dependent effects of the treatment than random sampling. We demonstrate the advantage of our method through both theoretical and numerical performance comparisons. The advantages are more pronounced when the trial cohort size is smaller, relative to the number of records in the database. Moreover, our approach causes no sampling bias in the estimated effects, for the same reason that DOE principles do not bias estimated effects. Although we focus on medical treatment assessment, the approach has applicability in many analytics application domains where one wants to conduct a controlled experimental study to identify the covariate-dependent effects of a factor (e.g., a marketing sales promotion), based on a sample of study subjects selected optimally from a large database of covariates.
Introduction
Controlled trials are considered the gold standard in investigating the effect of a treatment, but they are costly to run, with the cost depending on the number of participants enrolled in the trial. Controlled trials are especially useful in identifying the relationship between the covariates and the outcome. Traditional approaches to controlled trial design typically adopt random sampling and allocate patients to the treatment and control groups, in order to avoid biasing the treatment assignment and the estimated treatment effects (Schulz and Grimes, 2002) . These so-called randomized controlled trials involve several different types of randomization approaches, the simplest of which is unrestricted randomization. Also frequently used are restricted randomization approaches that include blocked randomization and stratified randomization (Lachin et al., 1988; Schulz and Grimes, 2002; Zhang et al., 2007) . A third type of approach is adaptive randomization, which includes covariateadaptive randomization and response-adaptive randomization (Lachin et al., 1988; Hu and Rosenberger, 2006; Zhang et al., 2007) . Most of the previous literature on the latter type focuses on the situation where patients arrive sequentially and, as each new patient arrives, one must decide to which group (treatment or control) the new patient should be allocated. There is also a large body of work on propensity scoring (D' Agostino, 1998) , in which one models the probability that a patient is selected for treatment as a function of the covariates and then incorporates CONTACT Daniel W. Apley apley@northwestern.edu Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/uiie. this propensity score model into the analysis. However, propensity scoring is largely inapplicable to the problem of trial design, as it applies to observational data in which patients have already been selected for treatment based on other considerations.
In contrast, taking advantage of the availability of databases containing covariate information on large numbers of patients, our proposed approach is to select upfront (in advance of conducting the study) a small, but informative, subset of patients from the database and to allocate each of the selected patients to either the treatment or the control group, in a manner that maximizes the amount of information in the cohort. To motivate and illustrate the approach, consider a health management provider that offers diabetes outreach to employees of large companies. They would like to conduct a study to assess whether participation by an at-risk patient in a new diabetes outreach program (the treatment factor) is effective at lowering the patient's risk (as measured by an appropriate outcome variable) and, if so, they would like to quantify the effect of the treatment, recognizing that the effect may depend on the levels of a number of other covariates, such as various demographic, blood test, and other health-related measures for that patient. They have such covariate information available for a large number of patients in their database, based on prior participation by the patients in other health management activities. Some form of controlled trial must be used, in which a small fraction of patients in the database are selected and allocated to either the control group or the treatment group.
In this article, we consider the more general situation where the goal is to select a trial cohort of patients for participation in a controlled trial study from an existing database containing patient covariates and then allocate each patient to either the control or treatment group. Rather than using random sampling and allocation, we propose an optimal Design Of Experiments (DOE) approach, in which patients are judiciously selected from the database and allocated based on their covariates. For a specified sample size, the DOE goal is to select and allocate (to either the treatment or control groups) the trial cohort to maximize the information content of the data, as it pertains to estimating the covariate-dependent effects of the treatment factor. This is a computationally intractable combinatorial optimization problem using today's technology. In light of this, we develop simple guidelines that provide insights into the nature of the optimal trial cohort and, based on this, an optimization algorithm for selecting the treatment and control groups. We refer to the approach as Designed Sampling from Databases (DSD) for controlled trials, and we demonstrate that it provides a far more informative study than random sampling and allocation. From an alternative perspective, to achieve the same level of accuracy in the covariate-dependent effects of the treatment, DSD needs a significantly smaller trial cohort size than random sampling. We also find that the advantages of our DSD method are more pronounced when the trial cohort size is smaller relative to the number of records in the database. It should be emphasized that although our DSD approach does not use random sampling, it introduces no sampling bias that might bias the estimated coefficients of the model. We elaborate on this point in the Conclusions.
We note that previous literature on covariate-adaptive randomization methods (Begg and Iglewicz, 1980; Atkinson, 1982; Begg and Kalish, 1984; Atkinson and Biswas, 2005; Antognini and Zagoraiou, 2011; Zhu et al., 2013) and the recent work of Bertsimas et al. (2015) have considered DOE-like criteria to allocate patients to treatment and control groups. However, these prior works assume that the full trial cohort has been predetermined by other means, and the objective reduces to allocating each patient in the fixed trial cohort to either the treatment or control cohorts. In contrast, in the present work we also use DOE concepts to select the most appropriate full trial cohort of patients for the study from among a very large set of patients in an existing database, which we demonstrate has enormous advantages. Moreover, we also use a batch DOE strategy that selects and allocates the entire trial cohort of patients in one shot, as opposed to the sequential DOE strategies in the previous literature on covariate-adaptive randomization that allocate patients one at a time. For a specified size, optimal batch designs are generally more powerful than their suboptimal sequential design counterparts.
This article is organized as follows. Section 2 is an overview of the DSD concepts and the underlying statistical model for the problem that we address. In Section 3, we derive an expression for the design optimality criterion for our statistical model. Based on this, in Section 4, we develop a heuristic optimization algorithm for efficiently solving (approximately) the DSD trial cohort design problem. Section 5 develops theoretical comparisons that demonstrate the performance superiority of DSD over random sampling. Section 6 confirms the performance advantages of DSD in the context of an example, and Section 7 concludes the article.
DSD concepts for clinical trial cohort design
In this section, we describe the underlying statistical model that we use to represent the covariate-dependent treatment effects and overview the DSD concepts that we use to design the clinical trial cohort. Assume that we have available a database containing covariate information (e.g., demographic and phenotypic information) for a large group of N patients. We are interested in the effect of a particular treatment on an outcome variable Y for the patients. Let z = ±1 denote the treatment variable for a patient, i.e., z = −1 if the patient is in the control group and z = 1 if the patient is in the treatment group. Suppose that we intend to design and collect a trial cohort of size 2n patients from this large cohort group of N patients (2n N, typically), with n patients allocated to the control group and n allocated to the treatment group. Also suppose that we have k covariates {x 1 , x 2 , . . . , x k } available for each patient and the treatment effect may depend on the covariates. To represent this situation, we assume the standard linear model with interactions between treatment and covariates:
where the subscript i is the patient index (or row index in the data array to which the regression model will be fit), ε i is the random error term for the ith patient, θ = [δ α β T γ T ] T are the model parameters to be estimated, β = [β 1 , β 2 , . . . , β k ] T , and γ = [γ 1 , γ 2 , . . . , γ k ] T . Rewriting Model (1) as (and omitting the patient index)
it follows that for a fixed set of covariate values {x 1 , x 2 , . . . , x k } for a patient, the covariate-dependent effect of the treatment is α + β 1 x 1 + · · · + β k x k . Consequently, our primary interest is in the parameters α and β, and our broad objective is to select and allocate the trial cohort of 2n patients to achieve the best possible estimates of these parameters of interest. Regarding the issue of patient nonparticipation and missing covariate data, we briefly discuss this in Section 7. Our DSD approach is to use DOE principles to select and allocate the most informative patients to comprise the trial cohort of 2n patients from the database of N patients for the controlled trial study. The objective of selecting a subset of patients from a database of covariate values is related to the active learning paradigm in the machine learning literature (Zhang and Oles, 2000; Hoi, Jin, Zhu, and Lyu, 2006; Hoi, Lin, and Lyu, 2006; Schein and Ungar, 2007; Settles, 2010) , in which one selects a subset of unlabeled (i.e., missing the response or outcome value) database records to be labeled by a human expert and used as the training data on which to fit some predictive model. However, active learning methods usually focus on classification (as opposed to regression) problems and select cases in a sequential (as opposed to batch) manner using criteria that focus on classification accuracy. Consequently, DOE concepts are more relevant to our problem.
In the traditional DOE literature, a number of methods have been developed to select the values of the design variables x = [x 1 , x 2 , . . . , x k ] T for the experimental cases to optimize some measure of quality of the resulting fitted model. The most common optimal DOE criteria when fitting linear regression models are the so-called "alphabetic" optimality criteria (e.g., Doptimality) (Pukelsheim, 2006; Montgomery, 2012) , and algorithmic design optimization is quite well-developed (Fedorov, 1972; Meyer and Nachtsheim, 1995; Goos and Jones, 2011) .
Existing optimal DOE methods and algorithms are not directly applicable to our situation, due to our restriction that we must sample patients from some larger set of patients in an existing database. First, our design space (the set of feasible values for x) is neither a continuous domain (common in the traditional DOE approach when the input factors are continuous variables) nor a region or sub-region of a grid (common in the traditional DOE approach when the input factors have discrete settings). Our design space is the set of existing x values for the N patients in the database. For large N, there are a great many possible x values to consider, and these data points typically have quite irregular structure, due to issues such as multicollinearity, clusters, outliers, etc., in the x-space. Second, when considering whether/how to modify an x value in the design, its elements cannot be modified independently, as in the coordinate exchange algorithm of Meyer and Nachtsheim ((1995) ; the most widely used DOE optimization algorithm), as only the fixed set of x values in the available data set is permissible. Our DOE optimization approach is closest to that of Ouyang et al. (2015) , who developed an optimal DOE-based algorithm for selecting a single validation sample of medical records from a large database of unreliable, error-prone records. Their setting is that a doctor chart-reviews the selected sample of records and determines whether each patient truly experienced a particular medical event, following which a logistic regression model is fitted to the validated data. In contrast, we consider the problem of not only selecting the sample of 2n patients but also allocating them to either the treatment or control cohorts; our setting is that a follow-up experiment is conducted on the treatment and control cohorts collectively, following which a linear regression model with interactions is fitted to the data to determine the covariate-dependent effect of the treatment. The simultaneous selection and allocation of the treatment and control cohorts makes for a much more complex optimization problem, and one of the contributions of this article is to exploit the structure of the problem to make the optimization tractable.
In this work, we use a D-optimality criterion to select and allocate our trial cohort of 2n patients. D-optimality seeks to minimize the determinant of the covariance matrix of the estimated parameters, which is based on the Fisher information matrix. Due to our need for selection and allocation, the optimization problem becomes much more complex than in Ouyang et al. (2015) . In the next section, we show that by taking into account the specific structure of the controlled trial problem, and by adding an additional, intuitively appealing design constraint, the D-optimality criterion for our DSD problem reduces to something that is quite tractable.
Derivation of the D-optimality criterion for Model
(1)
Rewrite Model (1) in regression matrix form as
assumed Gaussian and independent. It is straightforward to show that the overall regression design matrix is
where 1 is an n × 1 vector of ones, X − is the n × k design matrix for the group of n control patients, and X + is the n × k design matrix for the group of n treatment patients. That is,
for the group of n control patients, with the first subscript on x i j indicating the patient index. The n × k matrix X + is defined similarly but for the group of n treatment patients. From standard linear regression theory (Rao, 1973) , the Fisher information matrix is F = 1 σ 2 M T M, and the covariance matrix of the estimated regression parameterθ is F −1 . In our case:
where S + = 1 n X T + X + and S − = 1 n X T − X − are similar to the k × k sample covariance matrices (except that the sample average is not subtracted from the data) for the vector x = {x 1 , x 2 , . . . , x k } over the treatment and control groups, respectively, andx + and x − are the k × 1 sample average vectors for x over the treatment and control groups, respectively.
From Equation (4), we can reduce aliasing between the estimates of α, β, and γ by imposing the following design constraints (which will be ensured later in the optimization algorithm):x
The interpretation of these constraints is that we require the sample average vectors and sample covariance matrices of x to be similar for the control and treatment groups. This clearly has intuitive appeal, as one would expect that the patients chosen for the treatment group should be statistically similar to the patients chosen for the control group. It also has important implications that enable a computationally feasible, two-stage design optimization algorithm (see Section 4). With these constraints, the Fisher information matrix (4) becomes:
where 0 denotes a vector or matrix of zeros of appropriate dimension, and
is the 2n × k design matrix for x, andx is k × 1 average vector for x, both of which are over the entire trial cohort of 2n patients. By inverting Equation (6) and using results on the inverse of a partitioned matrix (Frazer et al., 1963) , the covariance matrix ofθ is
where
is the sample covariance matrix of x over the entire trial cohort of 2n patients, and we have used the relationship
From Equation (7), the covariance matrix of the regression estimates of α and β is
Due to the symmetry and block structure of Equation (7), it follows that Cov (δ,γ ) = Cov (α,β) and that {δ,γ} are uncorrelated (unaliased) with {α,β}. Consequently, |F −1 | = |Cov (α,β)| × |Cov (δ,γ )| = |Cov (α,β)| 2 , so that minimizing the overall D-optimality criterion |F −1 | is equivalent to minimizing |Cov (α,β)|, which is the D-optimality criterion for the parameters of primary interest. Using Equation (8) and results on the determinant of a partitioned matrix (Zhang, 2005) 
Consequently, our DSD optimal design strategy is simply to minimize |S −1 | or, equivalently, to maximize |S|, the determinant of the sample covariance matrix of the full trial cohort of 2n patients, while ensuring Constraints (5). This has important implications regarding the tractability and computational feasibility of the optimization algorithm for selecting and allocating the patients, as discussed in the next section.
Design optimization algorithm
Henceforth, we assume that, as a preprocessing step, one has standardized the k covariates by subtracting their average values and dividing by their standard deviations over all N patients in the database. This is necessary for a criterion such as D-optimality to be meaningful, and it is also recommended for improving numerical issues in regression analyses. Equation (9) shows that minimizing |Cov (α,β)| under the Constraints (5) is equivalent to maximizing
under the same constraints. Consequently, we can formulate our DSD cohort design problem as the combinatorial optimization problem
where . . . , x ik ] T , z + i has a value of 1 if patient i is selected for the treatment cohort and 0 otherwise, and z − i has a value of 1 if patient i is selected for the control group and 0 otherwise.
Simultaneously selecting and allocating (to either treatment or control cohort) the entire set of 2n patients to solve Model (10) as a full-fledged combinatorial optimization problem is computationally daunting for large N. However, from the results in Section 3, the objective function |S| depends on the selected cohort of 2n patients, but does not depend on their allocation to treatment or control groups. This suggests a much more computationally efficient two-stage heuristic, in which Stage 1 chooses the entire trial cohort of 2n patients from the large database of N patients to maximize |S|, without regard to their allocation, and then Stage 2 allocates the 2n patients to either the treatment or control group to enforce the constraintsx + ≈x − and S + ≈ S − .
The primary potential drawback of this two-stage heuristic, relative to a one-stage optimization in which the cohorts are simultaneously selected and allocated, is that the one-stage optimization may be able to slightly better ensure thatx + ≈x − and S + ≈ S − . However, in the numerical performance comparisons of Section 6, we demonstrate that the two-stage heuristic algorithm achieves treatment and control groups with very similar sample average and covariance. Moreover, the Constraints (5) cannot be exactly ensured anyway (because we have only a discrete set of N patients from which to choose), and attempting to enforce this too rigidly in the one-stage approach could result in a substantially smaller |S| and do more harm than good. Regardless, the computational advantages of the two-stage approach are enormous.
The remainder of this section describes the two-stage optimization algorithm in more detail. Regarding Stage 1, choosing the 2n out of N patients that exactly maximize | X T X 2n −xx T | is still a computationally intractable combinatorial optimization problem for large N. Consequently, we use a backward stepwise (greedy) approach, by which we start with all N patients in the database and, at each step, remove the single patient that least reduces | X T X 2n −xx T |, stopping when we have reduced the number of patients to the desired 2n. For a related optimization problem, in terms of solution quality and computational complexity, Ouyang et al. (2015) found the backwards stepwise approach to be more effective than a forwards stepwise approach or a forwards/backwards hybrid approach.
Let p denote the number of patients in the cohort at the current step, letx p denote the k × 1 sample average column vector for the p patients, and let X p denote the p × k design matrix for the p patients. Selecting the next patient to remove from the cohort requires calculating
T a total of p times (once for removing each of the p patients), the computational expense of which can be substantially reduced using the following recursive expressions. Let r denote the index of the patient considered for removal and x r their k × 1 vector of predictors. Noting that (X p−1 ) T X p−1 = (X p ) T X p − x r (x r ) T , we can recursively (going from p → p − 1) update all needed quantities via
and
Equations (11) to (13) follow from standard results on the determinant and the inverse of a rank-one modification of a matrix (Sherman and Morrison, 1950; Harville, 1997) . Equations (11) to (13) are iteratively executed for p = N, N−1, …, 2n + 1, until the desired size 2n is reached. On each iteration, they are repeated for each patient (i.e., each x r ) in the current p patients.
In Stage 2, after the 2n patients are selected in Stage 1, half of the 2n patients must be allocated to the control group and the other half to the treatment group. The Stage 2 criterion is to ensure thatx + ≈x − and S + ≈ S − per Constraints (5), in which case the overall optimization criterion |Cov (α,β)| depends only on the overall S for all 2n patients. We begin by randomly allocating n patients to the control group (comprising the rows of X − ) and the other n patients to the treatment group (comprising the rows of X + ), for which the Constraints (5) will typically be approximately satisfied. We then follow up by exchanging a pair of patients between the treatment and control groups, with the pair chosen to minimize the criterion 2||x + −x − || 2 + ||S + − S − || 2 after the exchange. Minimizing this criterion can be viewed as attempting to drive to zero the sum of squares of the off-diagonal elements of Equation (4) that are required to be zero in order for Equation (6) (and therefore Equation (9)) to hold. This exchange procedure is repeated until no further reduction in the criterion can be achieved. Each exchange requires searching over n 2 possible pairs of patients. One run of Matlab code takes about 40 minutes to find the optimal 2n patients and assign them to treatment and control groups on a desktop with Intel Core2 Duo CPU at 2.93 GHz and 4.00GB RAM. We summarize the entire DSD algorithm in Table 1 . 
Theoretical performance comparison of DSD and random sampling
First note that the Expression (8) for Cov (α,β) requires that x + =x − and S + = S − , which holds approximately for DSD (by design, since this is ensured in Stage 2 of the optimization algorithm) and for random sampling (by the nature of random sampling, as long as n is not too small). From Equation (9), |Cov (α,β)| ∝ |S| −1 also holds approximately for both DSD and random sampling. As DSD seeks to directly maximize |S| (i.e., minimize |Cov (α,β)|), it will generally result in a superior performance than random sampling if we consider |Cov (α,β)| as the performance criterion. DSD will also generally result in smaller standard deviations for the estimated parameters (α,β), which relate closely to |Cov (α,β)|, and we demonstrate that the improvement is substantial in the example in Section 6. Regarding the parameter α, which represents the effect of the treatment for a patient with covariates x = 0, Equation (8) implies that SD(α) achieves its minimum σ 2 2n when the sample averagex over the cohort of 2n patients is exactly zero. When x = 0, SD(α) is smaller when the Mahalanobis distancex T S −1x is smaller, which will generally be the case when S is larger. Even though DSD attempts to maximize |S|, we have observed in examples (see Section 6) that SD(α) is often slightly larger for DSD than for random sampling, asx is usually closer to 0 for random sampling (DSD ensures thatx + ≈x − in Stage 2 but not necessarily thatx ≈ 0 in Stage 1).
However, Var(α) by itself may not be particularly meaningful, as the effect of the treatment depends on the covariates x and, therefore, varies from patient to patient. The dramatic reduction in the standard deviation ofβ for the DSD approach will usually far outweigh the slight increase in the standard deviation ofα. To formalize this, consider that for a patient with covariates x = [x 1 , x 2 , . . . , x k ] T , the effect of the treatment (going from z = −1 to z = +1) on the outcome is
for new patients is generally of interest, and we would hope that the standard deviation SD (ˆ (x) ) of the predictor is low. Since this depends on the covariates x, as a measure of prediction quality, one might consider the average standard deviation:
averaged across all patients in the full database of size N. In Equation (14), each Var(ˆ (x i )) is given by
x i x T i denotes the "population" covariance matrix across the database of N patients, and we have used the fact that the "population" mean μ X ≡ 1 N N i=1 x i = 0, due to our convention of standardizing the covariates.
Letx RS and S RS denote the values ofx and S that result from random sampling and likewise forx DSD and S DSD . Due to the nature of random sampling,x RS will typically be close to the mean of the population μ X = 0, and S RS will typically be close to the population covariance X . In this case:
and the improvement in SD 2 (ˆ ) when using DSD, relative to random sampling, can be quantified as
where I denotes the identity matrix. The first term tr(I − X S −1 DSD ) in the right-hand-side of Equation (17) will virtually always be positive (assuming N n, which is the intended scenario). This is because Stage 1 of the DSD design optimization algorithm minimizes |S −1 DSD |, which will result in S DSD > X , i.e., the DSD sample covariance matrix will be larger than the population covariance matrix (by design). The term tr(I − X S −1 DSD ) thus represents the benefit that DSD can achieve via its attempt to choose the cohort to maximize |S DSD |. The second termx T DSD S −1 DSDxDSD represents a small penalty for using DSD, which results fromx DSD typically differing from 0 by more thanx RS and is closely related to Var(α DSD ) being slightly larger than Var(α RS ), as discussed earlier in this section. As the benefit tr(I − X S −1 DSD ) is generally much larger than the penaltyx T DSD S −1 DSDxDSD (again, by design), the net improvement in SD(ˆ ) achieved by DSD is generally substantially positive, as demonstrated in the example in the next section (see Table 4 and Fig. 2 in Section 6).
Example and numerical performance comparison
To evaluate our approach, we used a testbed data set containing information on the effect of statins (the treatment variable, z) on low-density lipoprotein (LDL) cholesterol (the outcome variable, y). The results are not meant to represent scientific findings but rather to illustrate the capabilities of our DSD method. We considered four covariates (x 1 to x 4 ), namely age, body mass index (bmi), diastolic blood pressure (bp_diastolic), and triglycerides (tri). A total of N = 11 080 patient records of these four covariates were considered from Northwestern Memorial Hospital EMR database from January 2006 to December 2010. The averages and standard deviations, respectively, of the raw outcome and covariates are 129.30 and 25.30 (for LDL cholesterol), 58.00 and 13.50 (for age), 30.19 and 7.45 (for bmi), 77.60 and 11.76 (for bp_diastolic), and 117.23 and 71.43 (for tri). All four covariates values were standardized prior to the subsequent analyses.
We applied our DSD approach to select a trial cohort of 2n = 1000 patients for a hypothetical controlled trial study, based on their covariate values for the real data set. To evaluate the performance of the approach, we calculated standard deviations for the estimated parameters of interest that would result from fitting the regression model (1) to the selected trial cohort. Notice that the standard deviations can be obtained directly as the square roots of the diagonal elements of the inverse of F in Equation (4), which depend only on n, σ , and the covariate values for the selected trial cohort. Notice also that σ 2 multiplies F −1 and, hence, the relative standard deviation performance when comparing two different methods for selecting the patients to enter the trial cohort is independent of σ . Consequently, we will assume a single value σ = 0.3 in the following comparisons.
We used Monte Carlo (MC) simulation with 10 000 MC replicates to compare the standard deviations of the estimated parametersθ that resulted from using our DSD approach to select and allocate the trial cohort, versus random sampling (i.e., randomly selecting a total of 2n patients and then randomly allocating half of them to the treatment group and the other half to the control group). For the random sampling method, on each Table  . Ratio of standard deviations (RS divided by DSD) for the estimated parameters for the treatment factor and its interactions with the covariates for random sampling (RS) versus DSD with different cohort sizes 2n. The standard deviations were averaged across   MC replicates. A ratio larger than . means DSD was better than RS by that factor. The values of the true parameters are in parentheses MC replicate we selected a different random trial cohort of 2n patients. For our DSD method, the trial cohort of 2n patients does not vary from replicate to replicate, since they are selected from the original data set of N patients. For this example, the standard deviations after the final Stage 2 allocation of the DSD method were very consistent for different "initial guess" random allocations at the beginning of Stage 2. More generally, if the standard deviations are found to depend on the initial guess, then one should use multiple initial guesses and choose the one that leads to the smallest standard deviation. The average standard deviations (averaged across the 10 000 MC replicates) for the treatment factor (α) and treatment-by-covariate interactions (β) are shown in Table 2 and plotted in Fig. 1 . Remarkably, Table 2 shows that the standard deviations for the estimates of the interaction terms (β) from our DSD approach are typically about half the standard deviations from random sampling. We also investigated different trial cohort sizes in Table 2 . When we decrease the size (i.e., smaller studies), the improvement in the standard deviations of the estimated parameters from the DSD approach (relative to random sampling) becomes more substantial. For example, for 2n = 100, the standard deviation ofβ 4 is five times smaller for DSD than for random sampling. Another way to interpret the results is that, in order to achieve the desired study accuracy (in terms of a desired standard deviation of the estimated parameters) DSD allows a far smaller study to be used than would random sampling. This can be seen in Fig. 1 , the five panels of which show the standard deviation of the estimated parameters with different cohort sizes for random sampling and for DSD. For example, in order to achieve a standard deviation of 0.01 forβ 2 , random sampling would require a cohort of about 970 patients, whereas DSD would require a much smaller cohort of only about 160 patients. This represents a substantial saving in resources needed to carry out the study.
The relative performance difference between DSD and random sampling depends to some extent on the ratio 2n N of trial cohort size to database population size. When the ratio 2n N is smaller, the performance improvement of DSD is generally larger. Intuitively, if 2n is almost as large as N, then the difference between the trial cohorts selected by DSD and by random sampling must be small. On the other hand, as the ratio 2n N becomes smaller, there is more potential for a marked difference between the DSD and random sampling trial cohorts. To verify this, we considered a smaller data set of size N = 1000 and a larger data set of size N = 100 000, both obtained from the original data set via bootstrapping, and then we selected cohorts of 2n = 100 patients from them using DSD and random sampling. Table 3 shows the ratio of standard deviations for α andβ from random sampling versus DSD (i.e., the standard deviation from random sampling, divided by standard deviation from DSD) when selecting 100 patients from the databases of size 1000, 11 080 (the size of the original database), and 100 000. These results were also averaged across 10 000 MC replicates. Forβ, we see that the ratio is increasing as N increases.
As discussed in Section 5 and confirmed in Tables 2 and 3, SD(α) is slightly larger (worse) for DSD than for random sampling. However, as also discussed in Section 5, the dramatic reduction in the standard deviation ofβ for the DSD approach far outweighs the slight increase in the standard deviation ofα, in the sense that DSD gives a much smaller average-treatmenteffect standard deviation SD(ˆ ) than random sampling. This is confirmed in Table 4 and Fig. 2 , which compare SD(ˆ ) over the population of size N = 11 080 for random sampling versus DSD for various cohort sizes 2n. The results in Table 4 and Fig. 2 , which are averages across 10 000 MC replicates, are after conversion back to unstandardized scale (so thatˆ and its standard deviation are in original LDL cholesterol units). Notice that as trial cohort size decreases relative to N, the ratio of SD(ˆ ) from random sampling to DSD increases. This is similar to what was observed in Tables 2 and 3 for the standard deviation of the individual parameters. Namely, the benefits of DSD over random sampling are greater when the database size N is larger, relative to the trial cohort size 2n. From Fig. 2 , in order to achieve an SD(ˆ ) ≈ 1 (for example), DSD requires a trial cohort of 500 patients, whereas random sampling would require a much larger cohort of over 1000 patients. To achieve SD(ˆ ) ≈ 2, random sampling requires a cohort that is about three times larger than DSD (310 versus 110 patients). In other words, using DSD we can achieve a comparable accuracy more efficiently, with a much smaller cohort. Notice that the improved performance of DSD, relative to random sampling, is despite the slightly worse SD(α).
The SD(ˆ ) curves in Fig. 2 use the exact Fisher information matrix from Equation (4), which does not assume that x + =x − or S + = S − . Although not shown in Fig. 2 or Table 4 , when we used the approximation in Equation (15), which is based on the assumption thatx + =x − and S + = S − , we found almost no visible difference between the exact and approximate curves for DSD. In comparison, the difference between the exact and approximate curves for random sampling was larger, which implies that using Stage 2 of the DSD algorithm to systematically enforce the similarity of the treatment and control cohorts, via the constraintsx + =x − and S + = S − , is more effective than leaving it to the random sampling mechanism. This is consistent with the findings of Bertsimas et al. (2015) , who demonstrated that using optimization techniques to allocate a pre-specified trial cohort to control and treatment groups can reduce their dissimilarity, relative to random sampling. When the further random sampling approximation thatx = 0 and S = X was assumed, as in Equations (16) and (17), the approximate random sampling curve was slightly lower than the exact random sampling curve shown in Fig. 2 . However, it was still substantially higher (worse) than the exact curve for DSD, which is consistent with theoretical results in Section 5.
Conclusions
This article presented a method that uses DOE concepts to judiciously select patients for a controlled trial study from a large patient database containing patient covariate information. The two-stage optimization algorithm in our DSD approach first selects in Stage 1 the overall trial cohort of 2n patients to enter into the study, and then in Stage 2 it subsequently allocates the 2n patients in the selected cohort to either treatment or control groups. Interestingly, we have shown that in order to optimally select the patients, it is sufficient to consider the sample covariance matrix of the patient covariates over the entire trial cohort of 2n patients, prior to consideration of their allocation to treatment/control groups. Then, in Stage 2, one simply allocates the 2n patients to either the treatment group or control group to ensure that the within-group mean vectors and covariance matrices are approximately equal. Exploiting these findings, we have developed a powerful, yet computationally tractable, optimization procedure for optimal design of the treatment and control groups. We have demonstrated via both theoretical and numerical comparisons that the proposed DSD approach can result in substantially lower standard deviations for the estimates of the covariate-dependent effects of the treatment and for the average effect of the treatment on the outcome, relative to random sampling. From an alternative viewpoint, our findings imply that to ensure a desired accuracy of the estimated parameters and covariate-dependent treatment effect, much lower trial cohort sizes are needed when using our DSD approach to select patients from a database, versus random sampling. We have also shown that the advantage of the DSD approach over random sampling is more pronounced for smaller studies relative to the size of the available database. This would result in significant cost savings when conducting such studies. We have focused on medical risk assessment as the application domain. However, our DSD approach should have broad applicability in many other analytics application domains in which one has available a large observational database of covariate values and the goal is to design a small, but powerful, controlled experimental study to identify the covariate-dependent effects of a particular factor. In this case, the DSD approach can be used to optimally design the experimental study. For example, suppose that a marketing goal is to determine the effect of a sales promotion on customer spend behavior, and the effect may depend on customer covariates such as demographic information, past purchasing behavior, etc. Instead of selecting (and allocating to either receive the promotion or to not receive it) a random sample of customers from the population of interest, the marketer could use our DSD approach to judiciously choose and allocate the sample of customers based on their covariate information from the database, resulting in a substantially more accurate predictive model than would random sampling.
We reiterate that our DSD approach introduces no sampling bias in the estimated coefficients, even though it does not use random sampling. This may sound surprising to some, given the prevalence of random sampling in clinical trials. However, keep in mind that fundamental DOE principles involve a very similar "non-random" mechanism. In any DOE, one judiciously selects a specific combination of factor settings for each experimental run, and these factor settings are not chosen randomly. They are, however, chosen without knowledge of the yet-to-berealized outcome value for that run, and this is what avoids the introduction of any bias in the estimated factor effects due to this type of non-random sampling. Otherwise, if DOE principles introduced a bias, then DOE would not be used as ubiquitously as it is in practice. Something quite similar occurs in our DSD approach. We judiciously select a specific combination of patient covariate data (analogous to the factor settings) for each selected patient (analogous to each experimental run) in the entire trial cohort (analogous to the entire experiment), and the patients are selected without consideration of their yet-to-be-realized outcome data. Consequently, as in the DOE approach, the nonrandom designed trial cohort selection in our DSD approach does not cause any biases. In fact, the judicious (non-random) trial cohort selection is precisely what results in a more informative data set being collected than would random sampling, much like how using optimal DOE principles results in a much more informative experiment than if the factor settings were chosen randomly.
It should be noted that the optimality of the DSD design is based on a particular criterion (D-optimality in this article) and on a particular assumed structure for the regression model. If the design is optimized under the assumptions in this article, but after the experiment is conducted it is decided that a regression model with (say) quadratic terms is needed, then the design will no longer be optimal. Ouyang et al. (2016) studied the impact of the assumed model structure and the design criterion on the nature of the sample design and on the quality of the resulting fitted model. They also investigated the impact of the characteristics of the covariate distribution (e.g., correlation or multicollinearity among covariates). Interested readers are referred to Ouyang et al. (2016) for details.
We close with a comment on patients who are selected for either the treatment or control groups but opt not to participate, which clearly affects the information content in the final (participating) study cohort and nullifies its optimality. How to take this into account in the sample selection procedure is a topic that merits further research.
